Welcome!

News Feed Item

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

NEW YORK, March 19, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability
http://www.reportlinker.com/p02052296/Epilepsy-Therapeutics-in-Asia-Pacific-Markets-to-2019---Treatment-Options-Enhanced-As-Novel-Next-Generation-AEDs-Show-Improved-Safety-and-Tolerability.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan. The report includes -
- A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options
- In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters
- A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target.
- Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action
- Multi-scenario forecasts of the epilepsy market from 2012 to 2019 in the four APAC regions
- In-depth analysis of licensing and co-development agreements and an overview of key agreements that could impact growth trends
- Key drivers and restraints that have had and are expected to have a significant impact upon the market

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Align your product portfolio to markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the anti-epileptic drugs market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
1 Table of Contents
1 Table of Contents 5

1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Disease Overview 8
2.2 Epidemiology 8
2.3 Symptoms 9
2.4 Etiology 10
2.5 Pathophysiology 10
2.6 Co-morbidities/Complications 11
2.7 Diagnosis 11
2.8 Prognosis 11
2.9 Treatment Efficacy 11
2.10 Treatment Options 12
2.10.1 Ion Channel Modulators 12
2.10.2 GABA-ergic Facilitation 12
2.10.3 Excitatory Amino Acid Inhibitors 12
2.10.4 Synaptic Modulators 12
2.11 Non-pharmacological Management 13
2.11.1 Lobectomy and Lesionectomy 13
2.11.2 Ketogenic Diet and Modified Atkins Diet 13

2.11.3 Vagus Nerve Stimulation 13
3 Epilepsy Therapeutic Landscape 14
3.1 Overview 14
3.2 Lyrica (pregabalin) 14
3.3 Lamictal (lamotrigine) 15
3.4 Keppra (levetiracetam) 16
3.5 Zonegran (zonisamide) 18
3.6 Vimpat (lacosamide) 19
3.7 Aptiom/Zebinix (eslicarbazepine acetate) 21
3.8 Fycompa (perampanel) 21
3.9 Trobalt/Potiga (ezogabine/retigabine) 22
3.10 Banzel/Inovelon (rufinamide) 23
3.11 Comparative Efficacy and Safety of Marketed Products 23
4 Pipeline for Epilepsy Therapeutics 26
4.1 Overall Pipeline 26
4.2 Pipeline by Mechanism of Action 28
4.3 Clinical Trials 29
4.3.1 Failure Rate 29
4.3.2 Patient Enrolment and Clinical Trial Size 31
4.3.3 Clinical Trial Duration 32
4.4 Promising Pipeline Candidates 33
4.4.1 Brivaracetam – UCB 33
4.4.2 Ganaxolone – Marinus Pharmaceuticals 33
5 Epilepsy Therapeutics Market Forecast to 2019 34
5.1 Geographical Markets 34
5.1.1 Key Asia-Pacific Markets 34
5.1.2 China 36

5.1.3 India 38
5.1.4 Japan 40
5.1.5 Australia 42
5.2 Drivers and Barriers 44
5.2.1 Drivers 44
5.2.2 Barriers 44
6 Deals and Strategic Consolidations 45
6.1 Deals Analysis 45
6.2 Research and Development Co-development Agreements 47
6.3 Research and Development Licensing Agreements 48
7 Appendix 50
7.1 Abbreviations 50
7.2 References 51
7.3 References for Heat Maps 55
7.4 Pipeline Products by Phase 56
7.4.1 Discovery 56
7.4.2 Preclinical 57
7.4.3 IND-filed and Phase 0 58
7.4.4 Phase I 58
7.4.5 Phase II 59
7.4.6 Phase III 60
7.4.7 Pre-registration 60
7.5 Market Forecasting Data Tables to 2019 61
7.5.1 Asia-Pacific 61
7.5.2 China 61
7.5.3 India 61
7.5.4 Japan 62
7.5.5 Australia 62

7.6 Research Methodology 62
7.6.1 Coverage 62
7.6.2 Secondary Research 63
7.6.3 Primary Research 63
7.6.4 Therapeutic Landscape 63
7.6.5 Geographical Landscape 66
7.6.6 Pipeline Analysis 66
7.7 Expert Panel Validation 66
7.8 Contact Us 66
7.9 Disclaimer 66

1.1 List of Tables
Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2013 8
Table 2: Epilepsy Therapeutics, Heat Maps for Efficacy and Safety of Marketed Products, References 55
Table 3: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Discovery), 2013 56
Table 4: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Preclinical), 2013 57
Table 5: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013 58
Table 6: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase I), 2013 58
Table 7: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase II), 2013 59
Table 8: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase III), 2013 60
Table 9: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Pre-registration), 2013 60
Table 10: Epilepsy Therapeutics, Asia-Pacific, Market Forecast, 2012–2019 61
Table 11: Epilepsy Therapeutics, China, Market Forecast, 2012–2019 61
Table 12: Epilepsy Therapeutics, India, Market Forecast, 2012–2019 61
Table 13: Epilepsy Therapeutics, Japan, Market Forecast, 2012–2019 62
Table 14: Epilepsy Therapeutics, Australia, Market Forecast, 2012–2019 62

1.2 List of Figures
Figure 1: Epilepsy Therapeutics, Epidemiology, Asia-Pacific, 2012 9
Figure 2: Epilepsy Therapeutics, Lyrica, Global, Revenue ($bn), 2013 15
Figure 3: Epilepsy Therapeutics, Lamictal, Global, Revenue ($m), 2009–2013 16
Figure 4: Epilepsy Therapeutics, Keppra, Global, Revenue ($bn), 2009–2013 17
Figure 5: Epilepsy Therapeutics, Zonegran, Global, Revenue ($m), 2009–2013 18
Figure 6: Epilepsy Therapeutics, Vimpat, Global, Revenue ($m), 2009–2013 20
Figure 7: Epilepsy Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013 24
Figure 8: Epilepsy Therapeutics, Global, Overall Pipeline Analysis, 2013 27
Figure 9: Epilepsy Therapeutics, Global, Pipeline Analysis, by Mechanism of Action, 2013 28
Figure 10: Epilepsy Therapeutics, Global, Clinical Trial Failure Rate, 2013 30
Figure 11: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Size, 2013 31
Figure 12: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Duration, 2013 32
Figure 13: Epilepsy Therapeutics, Asia-Pacific, Market Size, 2012–2019 35
Figure 14: Epilepsy Therapeutics, China, Market Size, 2012–2019 37
Figure 15: Epilepsy Therapeutics, India, Market Size, 2012–2019 39
Figure 16: Epilepsy Therapeutics, Japan, Market Size, 2012–2019 41
Figure 17: Epilepsy Therapeutics, Australia, Market Size, 2012–2019 43
Figure 18: Epilepsy Therapeutics, Deals by Region, Value and Year, 2006–2013 45
Figure 19: Epilepsy Therapeutics, Deals by Molecule Type and Mechanism of Action, 2006–2013 46
Figure 20: Epilepsy Therapeutics, Co-development Deals, Territory, 2006–2013 47
Figure 21: Epilepsy Therapeutics, Licensing Deals, by Territory, 2006–2013 48
Figure 22: GBI Research Market Forecasting Model 65

To order this report: Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability
http://www.reportlinker.com/p02052296/Epilepsy-Therapeutics-in-Asia-Pacific-Markets-to-2019---Treatment-Options-Enhanced-As-Novel-Next-Generation-AEDs-Show-Improved-Safety-and-Tolerability.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develo...
SYS-CON Events announced today that MangoApps will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device.
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effi...
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, explained how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
In today's uber-connected, consumer-centric, cloud-enabled, insights-driven, multi-device, global world, the focus of solutions has shifted from the product that is sold to the person who is buying the product or service. Enterprises have rebranded their business around the consumers of their products. The buyer is the person and the focus is not on the offering. The person is connected through multiple devices, wearables, at home, on the road, and in multiple locations, sometimes simultaneously...
“delaPlex Software provides software outsourcing services. We have a hybrid model where we have onshore developers and project managers that we can place anywhere in the U.S. or in Europe,” explained Manish Sachdeva, CEO at delaPlex Software, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor – all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
"We've discovered that after shows 80% if leads that people get, 80% of the conversations end up on the show floor, meaning people forget about it, people forget who they talk to, people forget that there are actual business opportunities to be had here so we try to help out and keep the conversations going," explained Jeff Mesnik, Founder and President of ContentMX, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Let’s face it, embracing new storage technologies, capabilities and upgrading to new hardware often adds complexity and increases costs. In his session at 18th Cloud Expo, Seth Oxenhorn, Vice President of Business Development & Alliances at FalconStor, discussed how a truly heterogeneous software-defined storage approach can add value to legacy platforms and heterogeneous environments. The result reduces complexity, significantly lowers cost, and provides IT organizations with improved efficienc...
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
"When you think about the data center today, there's constant evolution, The evolution of the data center and the needs of the consumer of technology change, and they change constantly," stated Matt Kalmenson, VP of Sales, Service and Cloud Providers at Veeam Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 19th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo Silicon Valley Call for Papers is now open.
The IoT is changing the way enterprises conduct business. In his session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, discussed how businesses can gain an edge over competitors by empowering consumers to take control through IoT. He cited examples such as a Washington, D.C.-based sports club that leveraged IoT and the cloud to develop a comprehensive booking system. He also highlighted how IoT can revitalize and restore outdated business models, making them profitable ...
In his session at @DevOpsSummit at 19th Cloud Expo, Yoseph Reuveni, Director of Software Engineering at Jet.com, will discuss Jet.com's journey into containerizing Microsoft-based technologies like C# and F# into Docker. He will talk about lessons learned and challenges faced, the Mono framework tryout and how they deployed everything into Azure cloud. Yoseph Reuveni is a technology leader with unique experience developing and running high throughput (over 1M tps) distributed systems with extre...